{"article": [{"url": "https://www.marketwatch.com/story/biontech-shares-jump-premarket-on-news-of-375-million-euros-in-german-funding-for-covid-19-vaccine-2020-09-15", "published": 1600152500.0, "headline": "BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine", "body": "BioNTech SE shares BNTX, +1.23% soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in funding from the German Federal Ministry of Education and Research to support the accelerated development of a COVID-19 vaccine in collaboration with partner Pfizer Inc. PFE, -0.27% and Fosun Pharma. The effort is one of three programs that the German ministry is funding with up to 750 million euros in total. BioNTech has also achieved five of eight defined milestones in developing a vaccine and has gained approval from the Paul-Ehrlich-Institut, to initiate the German arm of the global Phase 2/3 trial. The company has started recruiting patients on three continents and has enrolled more than 28,000 at sites in the U.S., Brazil, Argentina and Europe. Shares have gained 99% in the year to date, while the S&P 500 SPX, +0.87% has gained 4.7%."}]}